Version history

{
  "content_md": "# Validated Hypothesis: Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin\n\n> **Status**: ✅ Validated  |  **Composite Score**: 0.8066 (80th percentile among SciDEX hypotheses)  |  **Confidence**: Moderate\n\n**SciDEX ID**: `h-dffb42d9de`  \n**Disease Area**: biomarkers  \n**Primary Target Gene**: CHI3L1/TREM2/NRGN  \n**Hypothesis Type**: mechanistic  \n**Mechanism Category**: neuroinflammation  \n**Validation Date**: 2026-04-29  \n**Debates**: 1 multi-agent debate(s) completed  \n\n## Prediction Market Signal\n\nThe SciDEX prediction market currently prices this hypothesis at **0.767** (on a 0–1 scale), indicating strong market consensus for validation. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.\n\n## Composite Score Breakdown\n\nThe composite score of **0.8066** reflects SciDEX's 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:\n\n- **Confidence / Evidence Strength**: ██████░░░░ 0.680\n- **Novelty / Originality**: ██████░░░░ 0.650\n- **Experimental Feasibility**: ████████░░ 0.820\n- **Clinical / Scientific Impact**: ███████░░░ 0.780\n- **Mechanistic Plausibility**: ██████░░░░ 0.650\n- **Druggability**: ███████░░░ 0.700\n- **Safety Profile**: ████████░░ 0.850\n- **Competitive Landscape**: ███████░░░ 0.720\n- **Data Availability**: ████████░░ 0.800\n- **Reproducibility / Replicability**: ██████░░░░ 0.650\n\n## Mechanistic Overview\n\n## Mechanistic Overview\nIntegrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the claim that modulating CHI3L1/TREM2/NRGN within the disease context of biomarkers can redirect a disease-relevant process. The original description reads: \"## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the claim that modulating CHI3L1/TREM2/NRGN within the disease context of biomarkers can redirect a disease-relevant process. The original description reads: \"## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the claim that A weighted combinatorial algorithm combining a priming-associated marker (YKL-40), a microglial activation state marker (sTREM2), and a synaptic vulnerability marker (neurogranin) creates a composite fingerprint for identifying the temporal window before neurodegeneration. The multi-marker approach provides statistical robustness against individual marker limitations, though it inherits component weaknesses and carries overfitting risk requiring rigorous external validation. Framed more explicitly, the hypothesis centers CHI3L1/TREM2/NRGN within the broader disease setting of biomarkers. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating CHI3L1/TREM2/NRGN or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.68, novelty 0.65, feasibility 0.82, impact 0.78, mechanistic plausibility 0.65, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `CHI3L1/TREM2/NRGN` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within biomarkers, the working model should be treated as a circuit of stress propagation. Perturbation of CHI3L1/TREM2/NRGN or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. CSF YKL-40 and sTREM2 show distinct temporal patterns in AD progression. Identifier 32084334. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Multi-marker models outperform single biomarkers for AD prediction. Identifier 30814620. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Neurogranin reflects synaptic integrity and predicts progression. Identifier 29198979. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Inherits all component limitations; combining nonspecific markers does not create specificity. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Overfitting risk with 12 markers and elastic net regression requires stringent validation. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.73`, debate count `1`, citations `0`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: no_trials_found. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CHI3L1/TREM2/NRGN in a model matched to biomarkers. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin\". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting CHI3L1/TREM2/NRGN within the disease frame of biomarkers can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.\" Framed more explicitly, the hypothesis centers CHI3L1/TREM2/NRGN within the broader disease setting of biomarkers. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating CHI3L1/TREM2/NRGN or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.68, novelty 0.65, feasibility 0.82, impact 0.78, mechanistic plausibility 0.65, and clinical relevance 0.00. ## Molecular and Cellular Rationale The nominated target genes are `CHI3L1/TREM2/NRGN` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. No dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific. Within biomarkers, the working model should be treated as a circuit of stress propagation. Perturbation of CHI3L1/TREM2/NRGN or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. CSF YKL-40 and sTREM2 show distinct temporal patterns in AD progression. Identifier 32084334. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. Multi-marker models outperform single biomarkers for AD prediction. Identifier 30814620. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. Neurogranin reflects synaptic integrity and predicts progression. Identifier 29198979. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. Inherits all component limitations; combining nonspecific markers does not create specificity. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Overfitting risk with 12 markers and elastic net regression requires stringent validation. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.73`, debate count `1`, citations `0`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: no_trials_found. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CHI3L1/TREM2/NRGN in a model matched to biomarkers. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin\". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting CHI3L1/TREM2/NRGN within the disease frame of biomarkers can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.\" Framed more explicitly, the hypothesis centers CHI3L1/TREM2/NRGN within the broader disease setting of biomarkers. The row currently records status `proposed`, origin `debate_synthesizer`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating CHI3L1/TREM2/NRGN or the surrounding pathway space around not yet explicitly specified can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.68, novelty 0.65, feasibility 0.82, impact 0.78, mechanistic plausibility 0.65, and clinical relevance 0.00.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `CHI3L1/TREM2/NRGN` and the pathway label is `not yet explicitly specified`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nNo dedicated gene-expression context is stored on this row yet, so the biological rationale still leans heavily on the title, evidence claims, and disease framing. That gap should eventually be closed with single-cell or regional expression support because brain vulnerability is almost always cell-state specific.\nWithin biomarkers, the working model should be treated as a circuit of stress propagation. Perturbation of CHI3L1/TREM2/NRGN or not yet explicitly specified is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. CSF YKL-40 and sTREM2 show distinct temporal patterns in AD progression. Identifier 32084334. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Multi-marker models outperform single biomarkers for AD prediction. Identifier 30814620. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. Neurogranin reflects synaptic integrity and predicts progression. Identifier 29198979. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Inherits all component limitations; combining nonspecific markers does not create specificity. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Overfitting risk with 12 markers and elastic net regression requires stringent validation. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.73`, debate count `1`, citations `0`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: no_trials_found. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CHI3L1/TREM2/NRGN in a model matched to biomarkers. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting CHI3L1/TREM2/NRGN within the disease frame of biomarkers can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.\n\n## Evidence Summary\n\nThis hypothesis is supported by 8 lines of supporting evidence and 2 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.\n\n### Supporting Evidence\n\n1. CSF YKL-40 and sTREM2 show distinct temporal patterns in AD progression *([PMID:32084334](https://pubmed.ncbi.nlm.nih.gov/32084334/))*\n2. Multi-marker models outperform single biomarkers for AD prediction *([PMID:30814620](https://pubmed.ncbi.nlm.nih.gov/30814620/))*\n3. Neurogranin reflects synaptic integrity and predicts progression *([PMID:29198979](https://pubmed.ncbi.nlm.nih.gov/29198979/))*\n4. TREM2, microglia, and Alzheimer's disease. *(2021; Mech Ageing Dev; [PMID:33516818](https://pubmed.ncbi.nlm.nih.gov/33516818/); confidence: medium)*\n5. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy. *(2020; Cell; [PMID:32783918](https://pubmed.ncbi.nlm.nih.gov/32783918/); confidence: medium)*\n6. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. *(2024; Cancer Cell; [PMID:38788719](https://pubmed.ncbi.nlm.nih.gov/38788719/); confidence: medium)*\n7. TREM2: A new player in the tumor microenvironment. *(2023; Semin Immunol; [PMID:36989543](https://pubmed.ncbi.nlm.nih.gov/36989543/); confidence: medium)*\n8. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β(+) Macrophages. *(2025; Gastroenterology; [PMID:39956331](https://pubmed.ncbi.nlm.nih.gov/39956331/); confidence: medium)*\n\n### Opposing Evidence / Limitations\n\n1. Inherits all component limitations; combining nonspecific markers does not create specificity\n2. Overfitting risk with 12 markers and elastic net regression requires stringent validation\n\n## Testable Predictions\n\nSciDEX has registered **4** testable prediction(s) for this hypothesis. Key prediction categories include:\n\n1. **Biomarker prediction**: Modulation of CHI3L1/TREM2/NRGN expression/activity should produce measurable changes in biomarkers-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.\n2. **Cellular rescue**: Neurons or glia exposed to biomarkers conditions should show partial rescue of survival, morphology, or function when the relevant pathway is corrected.\n3. **Circuit-level effect**: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.\n4. **Translational signal**: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.\n\n## Proposed Experimental Design\n\n**Disease model**: Appropriate transgenic or induced biomarkers model (e.g., mouse, iPSC-derived neurons, organoid)  \n**Intervention**: Targeted modulation of CHI3L1/TREM2/NRGN   \n**Primary readout**: biomarkers-relevant functional, biochemical, or imaging endpoints  \n**Expected outcome if hypothesis true**: Partial rescue of biomarkers phenotypes; biomarker normalization  \n**Falsification criterion**: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results  \n\n## Therapeutic Implications\n\nThis hypothesis has a **moderate druggability score (0.700)**. Therapeutic approaches targeting CHI3L1/TREM2/NRGN are feasible but may require novel delivery strategies or combination approaches.\n\n**Safety considerations**: The safety profile score of 0.850 reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.\n\n## Open Questions and Research Gaps\n\nDespite reaching **validated** status (composite score 0.8066), several key questions remain open for this hypothesis:\n\n1. What is the optimal therapeutic window for intervening in the CHI3L1/TREM2/NRGN pathway in biomarkers?\n2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?\n3. How does the CHI3L1/TREM2/NRGN mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?\n4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?\n5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?\n\n## Related Validated Hypotheses\n\nThe following validated SciDEX hypotheses share mechanistic themes or disease context:\n\n_No closely related validated hypotheses found._\n\n## About SciDEX Hypothesis Validation\n\nSciDEX hypotheses reach **validated** status through a multi-stage evaluation pipeline:\n\n1. **Generation**: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis\n2. **Debate**: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions\n3. **Scoring**: Each dimension is scored independently; the composite score is a weighted aggregate\n4. **Validation**: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to 'validated' status\n5. **Publication**: Validated hypotheses receive structured wiki pages, enabling researcher access and citation\n\nThis page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.\n\n## External Resources\n\n- [NCBI Gene: CHI3L1/TREM2/NRGN](https://www.ncbi.nlm.nih.gov/gene/?term=CHI3L1/TREM2/NRGN)\n- [UniProt: CHI3L1/TREM2/NRGN](https://www.uniprot.org/uniprotkb?query=CHI3L1/TREM2/NRGN)\n- [PubMed: CHI3L1/TREM2/NRGN + biomarkers](https://pubmed.ncbi.nlm.nih.gov/?term=CHI3L1/TREM2/NRGN+biomarkers)\n- [OpenTargets: biomarkers Targets](https://platform.opentargets.org/disease/)\n- [ClinicalTrials.gov: biomarkers](https://clinicaltrials.gov/search?cond=biomarkers)\n",
  "entity_type": "hypothesis",
  "frontmatter_json": {
    "disease": "biomarkers",
    "validated": true,
    "target_gene": "CHI3L1/TREM2/NRGN",
    "hypothesis_id": "h-dffb42d9de",
    "composite_score": 0.806553
  },
  "refs_json": {
    "pmid29198979": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/29198979/",
      "pmid": "29198979",
      "year": null,
      "title": "",
      "authors": ""
    },
    "pmid30814620": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/30814620/",
      "pmid": "30814620",
      "year": null,
      "title": "",
      "authors": ""
    },
    "pmid32084334": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/32084334/",
      "pmid": "32084334",
      "year": null,
      "title": "",
      "authors": ""
    },
    "pmid32783918": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/32783918/",
      "pmid": "32783918",
      "year": "2020",
      "title": "",
      "authors": ""
    },
    "pmid33516818": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/33516818/",
      "pmid": "33516818",
      "year": "2021",
      "title": "",
      "authors": ""
    },
    "pmid36989543": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/36989543/",
      "pmid": "36989543",
      "year": "2023",
      "title": "",
      "authors": ""
    },
    "pmid38788719": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/38788719/",
      "pmid": "38788719",
      "year": "2024",
      "title": "",
      "authors": ""
    },
    "pmid39956331": {
      "url": "https://pubmed.ncbi.nlm.nih.gov/39956331/",
      "pmid": "39956331",
      "year": "2025",
      "title": "",
      "authors": ""
    }
  },
  "epistemic_status": "validated",
  "word_count": 3867,
  "source_repo": "SciDEX"
}